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Abstract 27 
Background:  Evidence suggests statins may improve survival in patients with bloodstream 28 
infections. However, there is no consensus on optimal timing and duration of exposure.  29 
Objectives: To quantify statin therapy duration associated with decreased mortality in 30 
bacteremic statin users.  31 
Methods: We conducted a case-control study using OptumClinformaticsTM with matched 32 
Premier hospital data (08/2009-03/2013). Cases who died during the hospitalization were 33 
matched 1:1 to survivors on disease risk scores (DRS). Post-admission statin therapy duration 34 
was evaluated in patients with at least 90 days of pre-admission continuous statin use. 35 
Classification and regression tree (CART) analysis was conducted to identify the optimal 36 
duration of statin continuation which provided the lowest inpatient mortality. Logistic regression 37 
was used to calculate the odds of mortality.  38 
Results: We included 58 DRS matched pairs of cases and controls: 47 patients (41%) 39 
continued statin therapy during the hospital admission, 15 (32%) cases and 32 (68%) controls. 40 
The CART analysis partitioned the continuation of statin therapy at ≥2 days, representing lower 41 
mortality for patients that continued statins for 2 days or more, and higher mortality for patients 42 
who did not continue or remained on statins for only 1 day. Inpatient mortality was 76% lower 43 
among those with at least 2 days of continued statin use (odds ratio 0.24, 95% confidence 44 
interval 0.11-0.55).  45 
Conclusions: Among matched cases and controls with at least 90 days of baseline statin use 46 
prior to the admission, the continuation of statins for at least 2 days after admission 47 
demonstrated a survival benefit among bacteremic patients. 48 
 49 
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Introduction 50 
 Inpatient mortality among patients with bloodstream infections remains high (16.3%).1 51 
Evidence from observational research suggests that statins may improve survival in patients 52 
with bacteremia2-5 and sepsis,6-8 including 14-day5, 15-day2, 31-180 day,9 and all-cause hospital 53 
mortality.3,7,5 While several studies have reported reduced mortality with statins in bacteremic 54 
patients, statin duration and measurement of outcomes differ across these studies.3-5  As a 55 
result, rates of survival vary, particularly as statin exposure varies.3,9 Additionally, several of 56 
these studies have identified an increase in mortality after cessation of statin therapy.3,10 Since 57 
the length of statin treatment time varies between studies, there is no consensus as to whether 58 
statin therapy should be continued among patients presenting to the hospital with bacteremia, 59 
and if so, what duration of statin continuation would provide the maximum advantage in terms of 60 
clinical outcomes.  61 
 62 
While several meta-analyses11,12 and observational3-5,9 studies observed protective 63 
effects with statins in bacteremia, one meta-analysis13 did not observe improvements in clinical 64 
outcomes with statin use. However, this meta-analysis was conducted among critically-ill 65 
patients with severe sepsis, and some of the included studies only had short durations of statin 66 
use.3,4,9 Other studies with shorter statin durations also did not demonstrate a statistically 67 
significant association between statin use and mortality.9,13,14 A recent randomized controlled 68 
trial (RCT) evaluating the potential benefits of continued statin therapy on inflammatory 69 
parameters and sepsis among patients with pre-existing statin use15 did not find clinical benefits 70 
with continuation. As such, there is a lack of consistent evidence regarding the appropriate 71 
exposure duration needed for statins to provide the greatest protective effects in bacteremic 72 
patients. The main objective of this study was to identify a duration of statin therapy continuation 73 
which minimized inpatient mortality among bacteremic patients. 74 
 75 
 4 
 
 76 
Methods 77 
 A case-control study design was used to estimate a time breakpoint in statin 78 
continuation at which the highest clinical benefit would be seen in terms of survival (i.e., lowest 79 
inpatient mortality). This study was conducted using de-identified OptumClinformaticsTM 80 
database (OptumInsight, Eden Prairie, MN) with matched Premier hospital data (10/01/2009-81 
03/31/2013) among adult (≥18 years) patients with a primary diagnosis of bacteremia during a 82 
hospital admission.  83 
 84 
 Adult patients with continuous enrollment for at least six months in the commercial 85 
health plan prior to hospital admission were included. Patients were included if they were 86 
hospitalized between 04/01/2010 and 03/31/2013 with a primary diagnosis of bacteremia or 87 
septicemia (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-88 
CM] codes 003.1, 020.2, 022.3, 036.2, 038.0, 038.1, 038.10-038.12, 038.19, 038.2, 038.3, 89 
038.40-038.44, 038.49, 038.8, 038.9, 054.5, 449, 771.81, 995.91, 995.92, 790.7)16 by any 90 
causative organism. We excluded patients who, on the first three days after hospital admission, 91 
did not receive a minimum of two successive days of at least one antibiotic therapy that would 92 
be used to treat bacteremia.17-20 The index date was defined as the date of the first hospital 93 
admission during the study period, and subsequent hospital admissions were not considered for 94 
the analysis. From this cohort, only patients with a minimum of 90 days of continuous statin use 95 
in the 90 days prior to admission were selected for inclusion to capture prevalent and adherent 96 
statin users (Figure 1). The Charlson comorbidity index and chronic comorbidities were 97 
captured from ICD-9-CM codes in the six months prior to admission and during the index 98 
admission.21 99 
 100 
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 Cases included those who died during the admission. Controls were selected from 101 
survivors of the same cohort of adult patients who had a primary diagnosis of bacteremia on 102 
hospital admission and received antibiotic therapy. Controls were matched to cases on disease 103 
risk scores (DRS).22 DRS is a confounder summary method, which can be used in case-control 104 
studies to control for confounding by calculating the predicated probability of an outcome in the 105 
absence of exposure.23,24 The stratified DRS is a retrospective balancing score and therefore it 106 
works in a similar manner in case-control studies as the propensity score works in cohort 107 
studies. While propensity score models predict the probability of exposure, DRS predict the 108 
probability of the outcome, which in our study was mortality.24 Disease risk scores were 109 
calculated using logistic regression. The c-statistic for the final DRS model was 0.91. The full 110 
DRS model equation can be found in the footnote of Figure 2. Using nearest neighbor matching 111 
within a caliper of 0.25 distance, a single control without replacement was selected for each 112 
case.25 We checked DRS balance between cases and controls using graphical displays (Figure 113 
2). 114 
 115 
Among patients with at least 90 days of statin therapy in the 90 days prior to admission 116 
(proportion of days covered 100% for all patients), the primary exposure of interest was the 117 
number of days of continued statin use during admission. The statins included were 118 
atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin. A one day gap in 119 
therapy was allowed, but the gap was not counted in the calculation of the statin use period. To 120 
partition statin continuation days associated with the greatest survival benefit, we conducted a 121 
classification and regression tree analysis (CART).26,27 The CART analysis, which includes an 122 
optimal tree selection based on pruning and cross-validation, identified subsets of patients at 123 
lowest risk of death based on days of statin continuation. CART models are useful because of 124 
their non-parametric, non-linear structure.27 The trees were automatically developed to forecast 125 
inpatient mortality by considering every possible cut-point on statin continuation duration at 126 
 6 
 
every node in the classification tree. Based on the split provided by the CART analysis, 127 
conditional logistic regression was conducted to calculate the odds of mortality. Statistical 128 
analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R software 129 
version 3.2.0 (The R Foundation for Statistical Computing) with a recursive partitioning 130 
technique “rpart” package that was developed for Splus (Insightful Corporation, Seattle, WA).28 131 
This study was reviewed and approved as exempt by the University of Rhode Island’s 132 
Institutional Review Board. 133 
  134 
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Results 135 
 Among our study population of prevalent and adherent statin users in the 90 days prior 136 
to admission, 61 (6.9%) patients died and 821 (93.1%) survived their hospital stay. Using DRS 137 
matching, controls were identified for 58 cases. Due to matching, baseline characteristics were 138 
similar between cases and controls, including age (median 68 vs. 67 years, p=0.8520; Table 1), 139 
gender (39.7% vs. 43.1% females, p=0.7992), race (20.7% vs. 15.5% non-whites, p=0.7637), 140 
and Charlson comorbidity score during the admission (median 4 vs. 4, p=0.8239) and in the six 141 
months prior to admission (median 4 vs. 4, p=0.4959). The length of hospital stay was 142 
significantly longer among controls compared to cases (median=9 vs. 5 days, p=0.0005). Of the 143 
47 (41%) patients who continued statin use during the hospital admission, 32% (n=15) were 144 
cases and 68% (n=32) were controls. The average statin therapy duration during admission 145 
among cases and controls was 1.5±3.7 vs. 4.5±7.5 days, respectively.  146 
  147 
The study included an equal number (n=58) of cases and controls, producing a 50% 148 
survival rate at the root node. The CART analysis partitioned the dependent variable of statin 149 
therapy duration at ≥2 days. Those continuing statin therapy for at least 2 days had a survival 150 
probability of 71.4%, while those not continuing or only continuing for 1 day had a survival 151 
probability of 37.8% (Figure 3). The odds of inpatient mortality was 76% lower among those 152 
continuing statin therapy for at least 2 days (OR 0.24, 95% CI 0.11-0.55). 153 
 154 
  155 
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Discussion 156 
 In this DRS matched case-control study, we identified a statin continuation duration 157 
threshold providing the maximum survival benefit among bacteremic patients. Our findings are 158 
consistent with existing literature3,4,9 evaluating this association, but we expanded these findings 159 
to identify an optimal statin duration of at least 2 days. Though other studies have observed 160 
similar protective effects with statin continuation3,4,9, as we observed in our study, duration of 161 
pre-admission statin therapy, with and without continuation, not only varied between these 162 
studies but also within studies. In considering our findings with those from previous studies, the 163 
period of statin exposure is directly related to crucial inflammatory periods, including as the 164 
infection develops (pre-admission statin exposure) and the time period right after admission 165 
when antibiotics are begun (continued statin exposure for at least those first 2 days).29,30 166 
 167 
A retrospective cohort study among bacteremic patients from a 300-bed acute care 168 
hospital in Ipswich, Australia found a reduced adjusted hospital mortality rate (OR 0.39, 95% CI 169 
0.17-0.91, p=0.029) in those taking statins prior to admission (n=66), which decreased even 170 
further with the continuation of statins (n=56) during the admission (OR 0.06, 95% CI 0.01-0.44, 171 
p=0.0056) compared to patients not receiving statins (n=372).3 Pre-admission statin use was 172 
based on medication use reported at admission, and therefore duration of prior statin use was 173 
not assessed. Similar effect estimates were observed when restricting the analysis to death 174 
attributable to bacteremia (statin use only before admission: OR 0.29, 95% CI 0.10-0.86, 175 
p=0.025; continued during admission: OR 0.09, 95% CI 0.01-0.64, p=0.016).3 Another 176 
retrospective cohort study4 conducted among bacteremic patients taking a statin at the time of 177 
admission and continuing throughout the hospitalization (n=35) at a Veterans Affairs Medical 178 
Center in Washington, identified a therapeutic benefit with statin continuation (adjusted OR 179 
0.13, 95% CI 0.02–0.99) compared with patients not taking statins (n=353). Again, duration of 180 
pre-admission statin use was not assessed.  181 
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 182 
These results should be taken into consideration with clinical judgment with regards to 183 
safety as they can contribute to liver dysfunction and life-threatening rhabdomyolysis.31,32 184 
Moreover, elevated statin levels have been observed in critical illness, possibly related to 185 
pharmacokinetic and pharmacodynamic changes during sepsis but also due to concomitantly 186 
prescribed medications with cytochrome P450 inhibition of statin metabolism.33,34 Among 187 
critically ill patients on continued statins, monitoring of liver function and creatine phosphokinase 188 
may be warranted. 189 
 190 
 Our study has a number of limitations. First, we were unable to assess statin drug or 191 
dose-dependent effects that might affect bacteremic mortality. Second, our study relied on a 192 
claims database, which is subject to misclassification due to coding selected for medical claims 193 
processing and reimbursement. Third, we could not study differences in mortality by causative 194 
pathogen. A previous study24 observed greater protection with statins in S. aureus bacteremia 195 
compared to bacteremia caused by Gram-negative bacilli, while also suggesting greater survival 196 
in nosocomial versus community-associated bacteremia.24 Our study could not evaluate these 197 
differences. We also could not distinguish bacteremic severity or changes in oral intake, 198 
however, we incorporated potential causative pathogen proxies (identified using ICD-9 codes) in 199 
our DRS model, as well as sepsis and ventilation status proxies from diagnosis-related group 200 
codes. Moreover, the sample size of our study was small. While we included antibiotic treatment 201 
in the DRS mode, we could not evaluate the appropriateness of antibiotic therapy. The intensity 202 
of statin therapy was also not assessed. Additionally, the limitations of CART analysis include 203 
an inability to fully describe the observed data due to uncertainty that remains in the prediction 204 
of the model and potential existence of multiple threshold values despite a single “optimal” 205 
split.35 Lastly, since statin use prior to admission was captured from pharmacy dispensings, 206 
misclassification due to non-adherence may have impacted our findings. 207 
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 208 
 In conclusion, we found that continuation of statins for at least 2 days in prevalent, 209 
adherent statin users, significantly reduced hospital mortality in our disease risk score matched 210 
case-control study conducted in a real-world clinical population. To further understand the 211 
relationship between statin use and improved clinical outcomes among those with serious 212 
infections, future research should assess drug/dose-response, while accounting for duration-213 
response. Although our findings indicate benefits with continuation of statins during admission, 214 
greater information is needed regarding the risks of continuation, in terms of adverse events, to 215 
enable a clear benefit-risk assessment.  216 
  217 
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Table 1. Demographic and hospitalization-related characteristics in cases and controls 218 
 219 
 220 
Data are median, standard deviation (sd) and interquartile range (IQR) or number and percent 221 
of patients. 222 
 223 
Characteristics 
Cases/ 
Died (n=58) 
Controls/ 
DRS matched 
survivors (n=58) P-value 
n/median 
%/IQR/s
d 
n/media
n 
%/IQR/sd 
Age (years) 68 61-77 67 60-82 0.8520 
Gender 
0.7061 Female 23 39.7 25 43.1 
Male 35 60.3 33 56.9 
Race 
0.7637 Non-white 12 20.7 9 15.5 
White 46 79.3 49 84.5 
Admitting physician specialty 
0.9190 
Intensive care/surgery <5 3.4 <5 3.4 
Medicine 18 31.0 16 27.6 
Other 38 65.6 40 69.0 
Ventilation status 
0.8095 Non-ventilation 47 81.0 48 82.8 
Ventilation 11 19.0 10 17.2 
Hospital admission year 
0.9494 
2010 10 17.3 9 15.5 
2011 18 31.0 21 36.2 
2012 30 51.7 28 48.3 
Statin therapy during admission 
0.0012 Average statin therapy 
duration (days) during 
admission  
1.5 3.7 4.5 7.5 
Hospital stay 
0.0005 
Length of hospital stay (days) 5 4-6 9 7-11 
Comorbidities (during admission) 
0.8239 
Charlson score  4 2-6 4 2-7 
Elixhauser score  6 4-8 6 5-8 0.2870 
Comorbidities (6 months prior to admission) 
0.4959 
Charlson score 4 2-8 4 1-7 
Elixhauser score 5 2-8 5 2-8 0.8413 
 12 
 
Figure 1:  Case-control study design  224 
 225 
 226 
 227 
 228 
 229 
 230 
 231 
Adult (≥18 years) inpatients with 
primary diagnosis of bacteremia 
(n=2,986) 
Adult (≥18 years) inpatients with Exclusions- 
 No antibiotic treatment within 2 
days of hospital admission 
(n=291) 
 
Premier data (n=25,649) Excluded-  
1. Missing medical record or not 
eligible- 6 months before 
hospital admission (N=5,647) 
2. Non-adults and patients 
without primary bacteremic 
diagnosis (n=17,016) 
 
Patients receiving any antibiotic within 
2 days of hospital admission (n=2,695) 
Premier data (n=25,649) 
Patients meeting inclusion criteria  
(n=882) 
 
Exclusions-Non-statin users and 
incident  statin users (patients 
without at least 90 days of 
continuous outpatient statin 
use, one day gap allowed) 
(n=1,813) 
 
 
Cases/Died (n=58) 
 
 
Controls/Survivors (n=58) 
 
Patients with inpatient mortality 
(n=61) 
 
Patients with no inpatient mortality 
(n=821) 
 
 
Matching on Disease Risk Scores 
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 232 
Figure 2:  Disease risk scores distribution among cases and controls 233 
 234 
 235 
Note: On the y-axis, 0 represent controls, while 1 represent cases. On the x-axis, estimated probability is 236 
the disease risk score. 237 
 238 
Variables included in the model: admission type, admission year, admitting physician specialty, age, 239 
anemia, antibiotic (initial and other use during admission), census region, Charlson comorbidity score 240 
during admission, chronic obstructive pulmonary disease, dyslipidemia, esophageal disorder, fluid and 241 
electrolyte disorder, gender, methicillin-resistant Staphylococcus aureus, neurological disorder, 242 
nutritional endocrine metabolic disorder, payor, race, sepsis, shock, ventilation, history of peripheral 243 
vascular disease, history of anemia, history of gastrointestinal disorders.   244 
 245 
Disease risk score (DRS):  246 
 14 
 
 247 
The disease risk score was the calculated probability of inpatient mortality among the unexposed group. 248 
Associations between the dependent variable (inpatient mortality) and independent variables 249 
(demographic, clinical, and hospitalization-related characteristics) were assessed with logistic 250 
regression. Variables with likelihood ratio test p-values <0.25 were included in the initial multivariate 251 
logistic regression model and then removed using step-wise backward elimination to arrive at the final 252 
DRS model, with all remaining p-values <0.05. The final DRS model was then used to calculate DRSs for 253 
the exposed group. Absence of multicollinearity was confirmed, as was goodness of fit. Using nearest 254 
neighbor matching within a restricted caliper distance of 0.25, one control was selected per case.  255 
 256 
 257 
 258 
 259 
 260 
 261 
 262 
 263 
 264 
 265 
 266 
 267 
 268 
 269 
 270 
 271 
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Figure 3: Partitioning from CART analysis 272 
 273 
 274 
 275 
 276 
 277 
  278 
 279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 
62.2% inpatient mortality 
(n=46 of 74) 
 
 
28.6% inpatient mortality 
(n=12 of 42) 
 
 
 
DRS matched population (n=116): 
 
Cases/Died (n=58) and Controls/Survivors (n=58) 
 
>= 2 days of statin use continued 
during admission (n=42) 
 
<2 days of statin use continued 
during admission (n=74)  
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